Dr. Jonathan Emberson

Biography

Jonathan Emberson is a Professor of Medical Statistics at Oxford Population Health and serves as a Principal Investigator for the Mexico City Prospective Study. His research primarily focuses on the causes and prevention of cardiovascular diseases through the design, conduct, analysis, and interpretation of large-scale observational cohort studies, randomized controlled trials, and individual-participant-data meta-analyses. Notable contributions include leading meta-analyses that have resulted in significant changes in the use of aspirin, statins, and blood pressure-lowering drugs for cardiovascular disease prevention, as well as advancements in thrombolytic therapy for patients with acute ischemic stroke. His work on the RECOVERY trial highlighted the effectiveness of dexamethasone in reducing mortality among the most severely ill hospitalized COVID-19 patients. Jonathan has been the UK Principal Investigator for the Mexico City Prospective Study since 2013, where he and his research team investigate both genetic and non-genetic factors contributing to premature morbidity and mortality in a cohort of 150,000 Mexican adults. Prior to joining the Clinical Trials Service Unit in 2004, he earned a BA in Mathematics and an MSc in Applied Statistics from the University of Oxford and obtained his PhD in Epidemiology from University College London, with prior experience in clinical trials epidemiology at the University of Sydney and University College London. He also supervises students at the MSc and DPhil levels and co-leads the Clinical Trials Meta-Analysis module in the MSc Global Health Science program at the Nuffield Department of Population Health.

Research Interests